Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Acquisitions & Divestments (2018 - 2026)

Viridian Therapeutics, Inc.\DE has reported Change in Acquisitions & Divestments over the past 8 years, most recently at $99.0 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $99.0 million for Q4 2025, down 16.78% from a year ago — trailing twelve months through Dec 2025 was $542.2 million (up 16.12% YoY), and the annual figure for FY2025 was $542.2 million, up 16.12%.
  • Change in Acquisitions & Divestments for Q4 2025 was $99.0 million at Viridian Therapeutics, Inc.\DE, down from $140.3 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for VRDN hit a ceiling of $171.4 million in Q1 2025 and a floor of -$497000.0 in Q2 2021.
  • Median Change in Acquisitions & Divestments over the past 5 years was $75.1 million (2021), compared with a mean of $77.3 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 3276.95% in 2021 and later crashed 78.92% in 2022.
  • Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments stood at $22.8 million in 2021, then soared by 65.67% to $37.7 million in 2022, then skyrocketed by 172.76% to $102.8 million in 2023, then increased by 15.7% to $119.0 million in 2024, then fell by 16.78% to $99.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $99.0 million (Q4 2025), $140.3 million (Q3 2025), and $131.5 million (Q2 2025) per Business Quant data.